Microbiome news - the latest biotech news from Labiotech.eu

Can the microbiome help the fight against infections?

Jim Cornall — Tue, 25 Jul 2023 09:30:00 +0000

Animals and humans coexist with a vast array of microorganisms known as the microbiome, forming a relationship that can range from mutually beneficial to pathogenic. To safeguard against harmful pathogens and maintain the presence of beneficial microorganisms, animals have evolved various defenses.One is small antimicrobial peptides (AMPs), small peptides that combat invading microbes. AMPs are […]

The post Can the microbiome help the fight against infections? appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Biomica announces interim positive results from irritable bowel syndrome program

Jim Cornall — Thu, 20 Jul 2023 10:00:00 +0000

Biomica Ltd., a clinical-stage biopharmaceutical company developing microbiome-based therapeutics, has released interim positive results from pre-clinical studies in its irritable bowel syndrome (IBS) program. The work was performed in collaboration with the lab of Kara Gross Margolis, associate director for clinical and translational research for the New York University Pain Research Center and an associate […]

The post Biomica announces interim positive results from irritable bowel syndrome program appeared first on Labiotech.eu.

SNIPR Biome sees positive results for first-in-human CRISPR microbial gene therapy

Jim Cornall — Thu, 01 Jun 2023 08:25:11 +0000

CRISPR-based microbial gene therapy company SNIPR Biome ApS has announced positive interim clinical results from its phase 1 clinical trial with SNIPR001. SNIPR Biome’s SNIPR001 is the first CRISPR-armed phage therapeutic developed to specifically target and remove E. coli, including antibiotic-resistant strains, from the human gastrointestinal tract. The work was supported by CARB-X, a global […]

The post SNIPR Biome sees positive results for first-in-human CRISPR microbial gene therapy appeared first on Labiotech.eu.

Pancreatic cancer microbiome discovery holds treatment hope

Jim Cornall — Tue, 30 May 2023 10:12:33 +0000

iNtRON Biotechnology has announced the identification of prophage and (non-) ORF-jamphage from the microbiome frequently observed in long-term pancreatic cancer survivors. The company said the ‘significant identification’ was achieved as part of its ongoing PHAGERIARUS development project conducted by the new drug part of the company. The PHAGERIARUS development project is focused on acquiring bacteriophage-derived […]

The post Pancreatic cancer microbiome discovery holds treatment hope appeared first on Labiotech.eu.

The six most advanced microbiome players aiming for the gut

Jonathan Smith — Mon, 15 May 2023 09:00:00 +0000

After decades of research, gut microbiome therapies are beginning to reach the market. Here are six of the companies harnessing the power of the microbiome to develop treatments derived from the gut. Over the years, gastrointestinal research has increasingly focused on the role of the microbe communities residing in our gut, known collectively as the […]

The post The six most advanced microbiome players aiming for the gut appeared first on Labiotech.eu.

The future of asthma treatment: is a cure possible?

Roohi Mariam Peter — Tue, 02 May 2023 11:00:32 +0000

For around 300 million people in the world, whipping out their inhaler – a medical device that delivers medicine to the lungs to open up narrowed airways – before puffing medicine into their mouth, is a typical response to wheezing, worsened by an asthma attack. While inhalers offer momentary relief, it is, however, no cure. […]

The post The future of asthma treatment: is a cure possible? appeared first on Labiotech.eu.

Vedanta Biosciences raises $106.5M for microbiome therapy

Jim Cornall — Thu, 27 Apr 2023 10:26:34 +0000

Vedanta Biosciences, a clinical-stage company developing a potential new category of oral therapies based on defined bacterial consortia, has raised $106.5 million. The funds will support pivotal-stage development of the U.S. company’s lead candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (CDI), and a phase 2 study of VE202 for ulcerative colitis, among […]

The post Vedanta Biosciences raises $106.5M for microbiome therapy appeared first on Labiotech.eu.

Progress in battle against stomach cancer

Jim Cornall — Wed, 26 Apr 2023 13:29:43 +0000

Researchers at Ludwig-Maximilians-Universität München (LMU) in Germany have discovered a weakness in the bacterium Helicobacter pylori, which could be exploited to develop new drugs.H. pylori, a pathogen responsible for widespread illnesses such as gastric ulcers and stomach cancer, has a weak point, which could be exploited to create new drugs. This was discovered by a […]

The post Progress in battle against stomach cancer appeared first on Labiotech.eu.

Gut microbiome: a promising target for Parkinson’s

Roohi Mariam Peter — Fri, 21 Apr 2023 11:08:47 +0000

Home to around a thousand microbial species, the gut’s role in nutrient and drug metabolism is pivotal for immune function. As trillions of bacteria that thrive in the gastrointestinal system aid in the metabolic activity, the gut microbiome can also be influential in therapeutic research for an array of diseases, including Parkinson’s. And of late, […]

The post Gut microbiome: a promising target for Parkinson’s appeared first on Labiotech.eu.

8 life science innovators you must meet at BioTrinity 2023

External Contributor — Thu, 20 Apr 2023 08:00:19 +0000

The post 8 life science innovators you must meet at BioTrinity 2023 appeared first on Labiotech.eu.

iNtRON looks to control colorectal cancer through microbiome

Jim Cornall — Tue, 04 Apr 2023 09:50:00 +0000

iNtRON Biotechnology has announced that it has demonstrated the effectiveness of P18-BE3CRC using a cancer organoid model. P18-BE3CRC is a drug candidate from iNtRON Biotechnology’s PHAGERIA platform technology, which is for the development and commercialization of bacteriophage-based drugs (Phageome API) for cancer control. Bacteriophages have been used for R&D on bacterial infectious diseases, but recently […]

The post iNtRON looks to control colorectal cancer through microbiome appeared first on Labiotech.eu.

Microbiome therapeutics biotech mbiomics raises €13M

Jim Cornall — Fri, 24 Mar 2023 10:00:00 +0000

mbiomics GmbH, a German microbiome biotech company developing the first generation of effective microbiome-based therapeutics has closed €13 million ($ 15 million) of a series A financing round led by MIG Capital. High-Tech Gründerfonds and Bayern Kapital joined the funding round together with a pool of private seed investors. mbiomics uses its proprietary, tailored high-resolution […]

The post Microbiome therapeutics biotech mbiomics raises €13M appeared first on Labiotech.eu.

Gut microbiota to be harnessed as a tool to diagnose diseases

Jim Cornall — Thu, 23 Mar 2023 11:30:00 +0000

A recent study at the University of Jyväskylä in Finland compared the gut microbiota and gut-derived metabolites between healthy controls and individuals with fatty liver. The results revealed that certain microbial metabolites are associated with liver fat content. The fact that the gut microbiota associates with many diseases has raised the hope that they could […]

The post Gut microbiota to be harnessed as a tool to diagnose diseases appeared first on Labiotech.eu.

How the microbiome can predict cancer immunotherapy success

Jim Cornall — Tue, 14 Mar 2023 10:18:24 +0000

A new study shows antibiotic treatment prior to CAR-T cell therapy is connected to unfavorable treatment outcomes. An international team headed by Eran Elinav of the Cancer & Microbiome Division of the German Cancer Research Center (DKFZ), and led by Christoph Stein-Thoeringer, professor of Clinical Infectiology and Translational Microbiome Research at the Medical Faculty of […]

The post How the microbiome can predict cancer immunotherapy success appeared first on Labiotech.eu.

Could new dementia treatment come from intestinal bacteria discovery?

Jim Cornall — Thu, 02 Mar 2023 11:24:55 +0000

Dementia with Lewy bodies (DLB), one of the most common forms of dementia, has no cure. Previous studies suggested that gut bacteria play a role in Parkinson’s disease, another neurodegenerative disorder, but the bacteria involved in dementia with Lewy bodies had not been identified. Now, a group led by researchers at the Nagoya University Graduate […]

The post Could new dementia treatment come from intestinal bacteria discovery? appeared first on Labiotech.eu.

The magical microbiome

External Contributor — Fri, 20 Jan 2023 10:11:25 +0000

By Brittany Niccum and Han Wei Now that we are past the holiday season and time when we might have over-indulged on rich foods, many of us are seeing how we can help our bodies bounce back. Science can help. Every environment – organic or inorganic – has a myriad of microorganisms living on the […]

The post The magical microbiome appeared first on Labiotech.eu.

EverImmune launches trial for oncobiotic lung and kidney cancer drug candidate

Jim Cornall — Tue, 17 Jan 2023 09:43:06 +0000

EverImmune, a clinical-stage biotechnology company specialized in the development of live biotherapeutic products in the field of microbiota oncology, says the first patient has been treated in its phase I clinical trial (EV 2101) evaluating Oncobax AK in lung and kidney cancer patients. The aim of the trial is to assess the toxicity and efficacy […]

The post EverImmune launches trial for oncobiotic lung and kidney cancer drug candidate appeared first on Labiotech.eu.

What’s in store for biotech in 2023?

Jim Cornall — Wed, 11 Jan 2023 08:34:21 +0000

Perhaps 2022 will best be remembered in the life science industry for the return of many of the face-to-face events that fell by the wayside during the COVID-19 pandemic. It might have been a mixed year for biotech companies, but 2023 is a new year, with new challenges, but also new opportunities. So what do […]

The post What’s in store for biotech in 2023? appeared first on Labiotech.eu.

2023 Editorial Calendar updated

Jim Cornall — Thu, 05 Jan 2023 09:36:26 +0000

Each month here at Labiotech.eu, we produce a special newsletter. While still news-related, these special editions are an opportunity to take a deeper look at topics of interest. It also allows us to focus on some of the special awareness days – of which there are many – associated with health and the life sciences. […]

The post 2023 Editorial Calendar updated appeared first on Labiotech.eu.

Biomica raises $20M to advance microbiome-based therapeutics pipeline

Jim Cornall — Wed, 21 Dec 2022 12:13:55 +0000

Biomica Ltd., a subsidiary of Evogene Ltd., has signed a definitive agreement for a $20 million financing round, to be led by Shanghai Healthcare Capital (SHC). The financing is subject to customary closing conditions, including clearance by Chinese regulatory authorities. The financing round will enable Biomica to develop its pipeline of microbiome-based therapeutics. The company […]

The post Biomica raises $20M to advance microbiome-based therapeutics pipeline appeared first on Labiotech.eu.